The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Anti-Inflammatory Biologics Market Over The 2026–2030 Period?
The anti-inflammatory biologics market has shown substantial expansion in recent years. It is anticipated to grow from $118.02 billion in 2025 to $128.84 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The past growth of this market is attributable to several factors, including the constrained availability of biologics, a reliance on traditional anti-inflammatory drugs, the increasing prevalence of rheumatoid arthritis and psoriasis, the development of hospital and clinic infrastructure, and rising investment in immunology research.
The anti-inflammatory biologics market size is poised for robust expansion over the next few years. It is forecast to swell to $180.93 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.9%. This projected growth during the forecast period is attributable to several factors, including the creation of next-generation cytokine inhibitors, an increase in home care and self-administration choices, a rise in regulatory approvals and more rapid clinical trial processes, increased investment in precision medicine and biologics research and development, and the formation of more partnerships between pharmaceutical and biotechnology companies. Significant trends anticipated during the forecast period involve the increasing uptake of targeted biologics for chronic inflammatory diseases, the broadening of subcutaneous and injectable drug delivery methods, an escalation in clinical trials and research for innovative anti-inflammatory biologics, a heightened emphasis on personalized treatment regimens, and greater awareness and access to biologics within emerging markets.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25695&type=smp
Which Major Factors Are Driving The Expansion Of The Anti-Inflammatory Biologics Market?
The escalating prevalence of arthritis is anticipated to stimulate the expansion of the anti-inflammatory biologics market in the foreseeable future. Arthritis, characterized by inflammation or swelling in one or more joints, leads to discomfort, stiffness, and diminished mobility, often worsening with advancing age. This uptick in arthritis cases is predominantly attributed to rising obesity levels, as excess body weight places additional strain on joints, contributing to inflammation and joint deterioration. Anti-inflammatory biologics effectively manage arthritis by targeting specific immune system components to mitigate inflammation, slow the progression of joint damage, alleviate symptoms, and enhance both physical function and overall quality of life for individuals with moderate to severe forms of the condition. As an illustration, in January 2024, data from the UK’s Office for Health Improvement and Disparities revealed that in 2023, 18.4% of people aged 16 and over reported having a long-term musculoskeletal (MSK) condition, marking an increase from 17.6% in 2022. Consequently, the increasing prevalence of arthritis acts as a significant catalyst for the growth of the anti-inflammatory biologics market.
How Is The Anti-Inflammatory Biologics Market Segmented Across Key Categories?
The anti-inflammatory biologics market covered in this report is segmented –
1) By Drug Class: Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, B-Cell Inhibitors, T-Cell Inhibitors, Other Drug Classes
2) By Route Of Administration: Oral, Injection, Intravenous, Subcutaneous
3) By Application: Rheumatoid Arthritis, Inflammatory Bowel Disease, Psoriasis, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-Users: Hospital, Clinics, Home Care Settings, Research And Academic Institutes
Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab, Infliximab, Etanercept, Golimumab, Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors, Interleukin-6 Inhibitors, Interleukin -12 Or 23 Inhibitors, Interleukin -17 Inhibitors, Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab, Ocrelizumab, Ofatumumab
4) By T-Cell Inhibitors: Abatacept, Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors, Anti-IgE And Other Biologics
Which Upcoming Trends Are Expected To Influence The Anti-Inflammatory Biologics Market?
Leading firms within the anti-inflammatory biologics market are concentrating on creating advanced treatments, including interleukin-6 (IL-6) receptor antagonists, designed to address chronic inflammatory conditions with enhanced precision and fewer adverse effects. These interleukin-6 (IL-6) receptor antagonists are biological medications that obstruct the IL-6 receptor, thereby diminishing inflammation and immune reactions in diseases like rheumatoid arthritis. As an illustration, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology enterprise, secured authorization from the US Food and Drug Administration (FDA) for Kevzara. This drug represents the initial and sole biologic therapy specifically for individuals suffering from polymyalgia rheumatica (PMR) who exhibit insufficient response to corticosteroids. Kevzara functions as a fully human monoclonal antibody that impedes the IL-6 receptor, assisting in alleviating the inflammation associated with PMR, a disorder primarily affecting older adults and characterized by muscle pain and stiffness. In contrast to conventional steroids, which can pose risks like osteoporosis and diabetes during extended administration, Kevzara offers a more precise, steroid-reducing method, leading to better patient results and heightened long-term safety.
Who Are The Dominant Players Shaping The Anti-Inflammatory Biologics Market Landscape?
Major companies operating in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc, UCB S.A
Read the full anti-inflammatory biologics market report here:
https://www.thebusinessresearchcompany.com/report/anti-inflammatory-biologics-global-market-report
Which Region Currently Holds The Largest Share Of The Anti-Inflammatory Biologics Market?
North America was the largest region in the anti-inflammatory biologics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-inflammatory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Anti-Inflammatory Biologics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25695&type=smp
Browse Through More Reports Similar to the Global Anti-Inflammatory Biologics Market 2026, By The Business Research Company
Anti Inflammatory Therapeutics Market Report 2026
Non Steroidal Anti Inflammatory Drugs Market Report 2026
Rare Inflammatory Disease Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model